Trial Profile
Randomized, Controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of WRAIR's AMA-1 Malaria Vaccine (FMP2.1) Adjuvanted in GSKBio's AS02A Vs. Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Malaria vaccine (Primary) ; AS02; Rabies vaccine
- Indications Falciparum malaria
- Focus Adverse reactions
- 19 Jun 2020 Results published in the Vaccine
- 14 Oct 2011 Additional lead trial centers identified as reported by ClinicalTrials.gov.
- 04 Feb 2009 Actual patient numbers (100) added as reported by ClinicalTrials.gov.